Goldman Sachs’s Ensysce Biosciences ENSC Stock Holding History

Goldman Sachs’s Portfolio ENSC Stock Details ENSC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-47	Closed	-$802K	–	6643
2021 Q4	$802K	Buy	+47	New	+$443K	﹤0.01%	5034

Other funds holding ENSC

HVCM

HG Vora Capital Management New York $197M AUM 17.92% 1-Year Est. Return

AFM

Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PIA

Powell Investment Advisors Miami, Florida $317M AUM 26.57% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Goldman Sachs's ENSC Position: Q1 2022 in Review

Goldman Sachs sold out of Ensysce Biosciences (ENSC) in Q1 2022, closing a stake of 47 shares — an estimated $802K sold.

Goldman Sachs first reported a position in ENSC in Q4 2021 and held it in 1 quarter. The position peaked at $802K in Q4 2021. 15 funds tracked by Wall St. Rank hold ENSC as of Q1 2022.

Goldman Sachs reported no remaining Ensysce Biosciences position as of Q1 2022 after selling out during the quarter.
Goldman Sachs sold 47 Ensysce Biosciences shares in Q1 2022, an estimated $802K.
Goldman Sachs first reported a position in Ensysce Biosciences in Q4 2021 and held it in 1 quarter.
Goldman Sachs's Ensysce Biosciences position peaked at $802K in Q4 2021.
15 funds tracked by Wall St. Rank held Ensysce Biosciences as of Q1 2022.

Based on Goldman Sachs's 13F filing for Q1 2022, filed 16 May 2022.